SION Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Given the investor's beginner level, long-term strategy, and available funds, Sionna Therapeutics (SION) is not a strong buy at this moment. While the company's innovative approach to cystic fibrosis treatment and positive analyst ratings are promising, the lack of significant financial growth, absence of recent news catalysts, and neutral trading sentiment suggest that this stock may not align with the user's goals for immediate investment.
The MACD is positive and expanding, indicating a potential upward trend. RSI is neutral at 54.879, and moving averages are converging, suggesting no clear momentum. The stock is trading near its pivot point of 37.302, with resistance at 39.267 and support at 35.336.
Analysts have provided strong ratings with price targets ranging from $58 to $63, citing promising preclinical data and a differentiated approach to cystic fibrosis treatment. The company is targeting a large market opportunity with innovative therapies.
The company's financials show no revenue growth, significant net losses, and a declining EPS. There is no recent news or significant trading activity from hedge funds, insiders, or Congress to drive momentum.
In Q3 2025, the company reported no revenue growth, a net income loss of -$20.28 million, and a 57.41% YoY decline in EPS to -0.46. Gross margin remains at 0%.
Analysts are optimistic, with multiple 'Outperform' and 'Buy' ratings. Price targets range from $58 to $63, supported by strong preclinical data and a large market opportunity in cystic fibrosis treatment.
